Background and aim: Symptoms compatible with irritable bowelsyndrome (IBS) are frequently present in patients with inflammatorybowel disease (IBD). A recent meta-analysis of patients withinflammatory bowel disease (IBD) demonstrated that 25–46%of those in clinical remission have symptoms compatible with adiagnosis of IBS. To evaluate the effectiveness of the administrationof a mixture of beta-glucan, inositol and digestive enzymes inimproving GI symptoms in IBD patients on clinical remission.Material and methods: The study was conducted in theGastroenterology Unit of the University of Catanzaro. Were enrolledpatients with a diagnosis of IBD performed by clinical, endoscopic,histological and radiological criteria. Patients were affected by IBD(CD, RCU) in clinical and endoscopic remission defined by HarveyBradshaw score <5 for CD and Mayo Score <2 for UC, in treatmentonly with systemical and topical mesalazine. All patients fulfillingthe Rome III citeria for the diagnosis of IBS. Were excluded fromthe study patients with IBD: UC and CD without strictures, whodid not report symptoms of IBS and in treatment by steroids,immunosuppressants and biological agents. The subjects includedin the study were randomized to receive Biointol® (one tablet afterlunch and after dinner) for four consecutive weeks (Group A), orany therapy (group B). Severity of symptoms at the entry and afterfour week was evaluated by means of 10 cm Visual Analogical Scales(VAS) in either group.Results: Were analyzed one hundred patients with IBD. Of these,sixty-two (62%) were in clinical remission: 33 were male (53%),median age of 51 years. 29 (46%) were affected by CD and 33 (53%)by UC. 14 (22%) were smokers. All patients completed the study tofour weeks. At enrollment there were no significant differencesbetween the two treatment groups. After four weeks of treatment,in the group A there was a statistically significant reductioncompared to the group B in abdominal pain (mean VAS score 2 ± 2VS 4 ± 3 p <0.001) in bloating (mean VAS score 4 ± 3 VS 1 ± 1 p<0.001) and flatulence (mean VAS score 4 ± 3 VS 7 ± 1 p 0.006)Conclusions: Few studies have been conducted previously toidentify the association between IBS and IBD. For the first time,in this work, was evaluated the effect of the administration of amixture of beta-glucan, inositol and digestive enzymes. Thesefindings could pave the way to better characterize the pathogenesisof IBS and IBD. Further studies are needed to clarify the effectivenessof this evidence

BETA-GLUCAN, INOSITOL AND DIGESTIVE ENZYMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE ASSOCIATED WITH IRRITABLE BOWEL SYNDROME

Spagnuolo R;
2016-01-01

Abstract

Background and aim: Symptoms compatible with irritable bowelsyndrome (IBS) are frequently present in patients with inflammatorybowel disease (IBD). A recent meta-analysis of patients withinflammatory bowel disease (IBD) demonstrated that 25–46%of those in clinical remission have symptoms compatible with adiagnosis of IBS. To evaluate the effectiveness of the administrationof a mixture of beta-glucan, inositol and digestive enzymes inimproving GI symptoms in IBD patients on clinical remission.Material and methods: The study was conducted in theGastroenterology Unit of the University of Catanzaro. Were enrolledpatients with a diagnosis of IBD performed by clinical, endoscopic,histological and radiological criteria. Patients were affected by IBD(CD, RCU) in clinical and endoscopic remission defined by HarveyBradshaw score <5 for CD and Mayo Score <2 for UC, in treatmentonly with systemical and topical mesalazine. All patients fulfillingthe Rome III citeria for the diagnosis of IBS. Were excluded fromthe study patients with IBD: UC and CD without strictures, whodid not report symptoms of IBS and in treatment by steroids,immunosuppressants and biological agents. The subjects includedin the study were randomized to receive Biointol® (one tablet afterlunch and after dinner) for four consecutive weeks (Group A), orany therapy (group B). Severity of symptoms at the entry and afterfour week was evaluated by means of 10 cm Visual Analogical Scales(VAS) in either group.Results: Were analyzed one hundred patients with IBD. Of these,sixty-two (62%) were in clinical remission: 33 were male (53%),median age of 51 years. 29 (46%) were affected by CD and 33 (53%)by UC. 14 (22%) were smokers. All patients completed the study tofour weeks. At enrollment there were no significant differencesbetween the two treatment groups. After four weeks of treatment,in the group A there was a statistically significant reductioncompared to the group B in abdominal pain (mean VAS score 2 ± 2VS 4 ± 3 p <0.001) in bloating (mean VAS score 4 ± 3 VS 1 ± 1 p<0.001) and flatulence (mean VAS score 4 ± 3 VS 7 ± 1 p 0.006)Conclusions: Few studies have been conducted previously toidentify the association between IBS and IBD. For the first time,in this work, was evaluated the effect of the administration of amixture of beta-glucan, inositol and digestive enzymes. Thesefindings could pave the way to better characterize the pathogenesisof IBS and IBD. Further studies are needed to clarify the effectivenessof this evidence
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/711
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact